G protein-coupled receptors revisited: therapeutic applications inspired by synthetic biology.

G protein-coupled receptors (GPCRs) mediate the majority of cellular responses to hormones and neurotransmitters within the human body. They have much potential in the emerging field of synthetic biology, which is the rational, systematic design of biological systems with desired functionality. The responsiveness of GPCRs to a plethora of endogenous and exogenous ligands and stimuli make them ideal sensory receptor modules of synthetic gene networks. Such networks can activate target gene expression in response to a specific stimulus. Additionally, because GPCRs are important pharmacological targets of various human diseases, genes encoding their protein/peptide ligands can also be incorporated as target genes of the response output elements of synthetic gene networks. This review aims to critically examine the potential role of GPCRs in constructing therapeutic synthetic gene networks and to discuss various challenges in utilizing GPCRs for synthetic biology applications.

[1]  V. Brinkmann.  Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.

[2]  S. Milano,et al.  Regulation of receptor trafficking by GRKs and arrestins. , 2007, Annual review of physiology.

[3]  M. Vincent,et al.  The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. , 2009, Arquivos de neuro-psiquiatria.

[4]  M. Fussenegger,et al.  Optogenetic therapeutic cell implants. , 2012, Gastroenterology.

[5]  M. Haluzík,et al.  The Peptidic GHS-R antagonist [D-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity , 2011, Molecular and Cellular Endocrinology.

[6]  R. Leurs,et al.  Virally encoded G protein-coupled receptors: targets for potentially innovative anti-viral drug development. , 2003, Current drug targets.

[7]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[8]  T. Kenakin,et al.  Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. , 2011, Methods in molecular biology.

[9]  Deepak Chandran,et al.  Computer-aided design of biological circuits using tinkercell , 2010, Bioengineered bugs.

[10]  Shuyun Dong,et al.  Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs , 2010, Nature Protocols.

[11]  D. Armentano,et al.  Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes , 2007, Gene Therapy.

[12]  M. Thompson,et al.  Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. , 2008, Methods in molecular biology.

[13]  Dali Li,et al.  Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets , 2012, Acta Pharmacologica Sinica.

[14]  Martin Fussenegger,et al.  Engineering of synthetic mammalian gene networks. , 2009, Chemistry & biology.

[15]  H. Akil,et al.  Controlling signaling with a specifically designed Gi-coupled receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Timothy K Lu,et al.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.

[17]  Natalio Krasnogor,et al.  The Infobiotics Workbench: an integrated in silico modelling platform for Systems and Synthetic Biology , 2011, Bioinform..

[18]  P. Wedegaertner,et al.  Non-canonical signaling and localizations of heterotrimeric G proteins. , 2012, Cellular signalling.

[19]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[20]  M. Dufau.  The luteinizing hormone receptor. , 1998, Annual review of physiology.

[21]  L J Gray,et al.  Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta‐analysis , 2012, Diabetes, obesity & metabolism.

[22]  K. Klotz.  Adenosine receptors and their ligands , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[23]  Martin Fussenegger,et al.  Synthetic gene networks in mammalian cells. , 2010, Current opinion in biotechnology.

[24]  John C March,et al.  Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model , 2010, Proceedings of the National Academy of Sciences.

[25]  Michelle L. Collins,et al.  The Preparation of Primary Hematopoietic Cell Cultures From Murine Bone Marrow for Electroporation , 2009, Journal of visualized experiments : JoVE.

[26]  E. S. Graham,et al.  Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease , 2010, British journal of pharmacology.

[27]  J. Bockaert,et al.  A Single Mutation in the 5-HT4 Receptor (5-HT4-R D100(3.32)A) Generates a Gs-coupled Receptor Activated Exclusively by Synthetic Ligands (RASSL)* , 2003, The Journal of Biological Chemistry.

[28]  E. Brown,et al.  Signaling through the extracellular calcium-sensing receptor (CaSR). , 2012, Advances in experimental medicine and biology.

[29]  B. Conklin,et al.  Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice , 1999, Nature Biotechnology.

[30]  M. Kikuya,et al.  Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements , 2003, Journal of hypertension.

[31]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[32]  N. Zhou,et al.  An update of novel screening methods for GPCR in drug discovery , 2012, Expert opinion on drug discovery.

[33]  Erwin W. Gelfand,et al.  The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines , 2008, Nature Reviews Drug Discovery.

[34]  K. Jacobson,et al.  Orthogonal activation of the reengineered A3 adenosine receptor (neoceptor) using tailored nucleoside agonists. , 2006, Journal of medicinal chemistry.

[35]  G. P. Raju,et al.  Hedgehog inhibition as an anti-cancer strategy. , 2012, Vitamins and hormones.

[36]  E. Montanya.  A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes , 2012, Expert opinion on pharmacotherapy.

[37]  T. Wilkin,et al.  CCR5 antagonism in HIV infection: current concepts and future opportunities. , 2012, Annual review of medicine.

[38]  Pamela A Silver,et al.  Synthetic biology: exploring and exploiting genetic modularity through the design of novel biological networks. , 2009, Molecular bioSystems.

[39]  G. Salisbury,et al.  Fertility Level in Artificial Breeding Associated with Season, Hours of Daylight, and the Age of Cattle , 1947 .

[40]  P. Marin,et al.  5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. , 2013, ACS chemical neuroscience.

[41]  Kenji F. Tanaka,et al.  The manipulation of neural and cellular activities by ectopic expression of melanopsin , 2013, Neuroscience Research.

[42]  H. Friess,et al.  Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. , 2006, Cancer letters.

[43]  Light-regulated gene expression in yeast. , 2012, Methods in molecular biology.

[44]  J. Salamone,et al.  Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. , 1999, European journal of pharmacology.

[45]  J. Wess,et al.  Engineering GPCR signaling pathways with RASSLs , 2008, Nature Methods.

[46]  D. Watanabe,et al.  Glutamate receptors: brain function and signal transduction 1 Published on the World Wide Web on 21 October 1997. 1 , 1998, Brain Research Reviews.

[47]  B. Roth,et al.  New Insights into the Function of M4 Muscarinic Acetylcholine Receptors Gained Using a Novel Allosteric Modulator and a DREADD (Designer Receptor Exclusively Activated by a Designer Drug) , 2008, Molecular Pharmacology.

[48]  R. Eglen,et al.  New insights into GPCR function: implications for HTS. , 2009, Methods in molecular biology.

[49]  Graeme Milligan,et al.  G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology , 2004, Molecular Pharmacology.

[50]  E. D. de Vries,et al.  A review on CXCR4/CXCL12 axis in oncology: no place to hide. , 2013, European journal of cancer.

[51]  J. Gutkind,et al.  G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.

[52]  K. Defea,et al.  β‐arrestins and heterotrimeric G‐proteins: collaborators and competitors in signal transduction , 2008, British journal of pharmacology.

[53]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[54]  M. Fussenegger,et al.  A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells , 2004, Investigational New Drugs.

[55]  L. Luttrell,et al.  ‘Biasing’ the parathyroid hormone receptor: A novel anabolic approach to increasing bone mass? , 2011, British journal of pharmacology.

[56]  Martin Fussenegger,et al.  Recent advances in mammalian synthetic biology-design of synthetic transgene control networks. , 2009, Current opinion in biotechnology.

[57]  Achuthsankar S. Nair,et al.  Programming languages for synthetic biology , 2010, Systems and Synthetic Biology.

[58]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[59]  M. Sallese,et al.  Regulation of G‐protein‐coupled receptor kinase subtypes by calcium sensor proteins , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  R. Berne,et al.  Protective Effects of Adenosine In Myocardial Ischemia , 1992, Circulation.

[61]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[62]  P. A. Friedman,et al.  Role of PDZ proteins in regulating trafficking, signaling, and function of GPCRs: means, motif, and opportunity. , 2011, Advances in pharmacology.

[63]  B. Stoica,et al.  MGLuR5 activation reduces β‐amyloid‐induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis‐inducing factor , 2004, Journal of neurochemistry.

[64]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[65]  N. Ryba,et al.  The Receptors for Mammalian Sweet and Umami Taste , 2003, Cell.

[66]  C. Lindsley,et al.  Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl)benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists. , 2010, Bioorganic & medicinal chemistry letters.

[67]  E. Kelly,et al.  Agonist‐selective mechanisms of GPCR desensitization , 2008, British journal of pharmacology.

[68]  B. Roth,et al.  Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand , 2007, Proceedings of the National Academy of Sciences.

[69]  M. S. Repka-Ramirez,et al.  New concepts of histamine receptors and actions , 2003, Current allergy and asthma reports.

[70]  Michel Bouvier,et al.  Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. , 2005, Trends in pharmacological sciences.

[71]  Christopher K Surratt,et al.  G protein-coupled receptor structural motifs: relevance to the opioid receptors. , 2005, Current topics in medicinal chemistry.

[72]  H. Schiöth,et al.  G protein-coupled receptor deorphanizations. , 2013, Annual review of pharmacology and toxicology.

[73]  B. Conklin,et al.  Engineering receptors activated solely by synthetic ligands (RASSLs). , 2001, Trends in pharmacological sciences.

[74]  A. Chess,et al.  Function of Rhodopsin in Temperature Discrimination in Drosophila , 2011, Science.

[75]  Sid Topiol,et al.  X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.

[76]  Yiannis N. Kaznessis,et al.  SynBioSS designer: a web-based tool for the automated generation of kinetic models for synthetic biological constructs , 2010, Briefings Bioinform..

[77]  R. Gainetdinov,et al.  Physiological roles of G protein-coupled receptor kinases and arrestins. , 2007, Annual review of physiology.

[78]  J. Nielsen,et al.  Opportunities for yeast metabolic engineering: Lessons from synthetic biology , 2011, Biotechnology journal.

[79]  B Kemp,et al.  Various behavioral signs of estrous and their relationship with time of ovulation in dairy cattle. , 2005, Theriogenology.

[80]  P. Sexton,et al.  GPCR modulation by RAMPs. , 2006, Pharmacology & therapeutics.

[81]  L. Devi,et al.  Structural biology: How opioid drugs bind to receptors , 2012, Nature.

[82]  T. Murakami,et al.  Role of CXCR4 in HIV infection and its potential as a therapeutic target. , 2010, Future microbiology.

[83]  Raag D. Airan,et al.  Temporally precise in vivo control of intracellular signalling , 2009, Nature.

[84]  J. Dias,et al.  Multiple facets of follicle-stimulating hormone receptor function , 2007, Endocrine.

[85]  Martin Fussenegger,et al.  Self-sufficient control of urate homeostasis in mice by a synthetic circuit , 2010, Nature Biotechnology.

[86]  G. Barnea,et al.  The genetic design of signaling cascades to record receptor activation , 2008, Proceedings of the National Academy of Sciences.

[87]  A. Mushegian,et al.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. , 2012, Pharmacology & therapeutics.

[88]  J. Mallol,et al.  Basic Concepts in G-Protein-Coupled Receptor Homo- and Heterodimerization , 2007, TheScientificWorldJournal.

[89]  Christina D Smolke,et al.  Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems , 2010, Proceedings of the National Academy of Sciences.

[90]  Martin Fussenegger,et al.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome , 2012, Proceedings of the National Academy of Sciences.

[91]  Christopher A. Voigt,et al.  Environmentally controlled invasion of cancer cells by engineered bacteria. , 2006, Journal of molecular biology.

[92]  Bruce R. Conklin,et al.  Engineering the Melanocortin-4 Receptor to Control Constitutive and Ligand-Mediated Gs Signaling In Vivo , 2007, PloS one.

[93]  J. Trejo.  Internal PDZ Ligands: Novel Endocytic Recycling Motifs for G Protein-Coupled Receptors , 2005, Molecular Pharmacology.

[94]  Stuart L. Schreiber,et al.  SnapShot: Ca2+-Calcineurin-NFATSignaling , 2009, Cell.

[95]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[96]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[97]  Kari A. Johnson,et al.  Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 , 2008, Molecular Pharmacology.

[98]  Liaoyuan A. Hu,et al.  Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. , 2009, The Biochemical journal.

[99]  James J. Collins,et al.  Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.

[100]  S. A. Johnston,et al.  Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase. , 1994, Analytical biochemistry.

[101]  A. Gilman,et al.  G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.

[102]  M. Bednarek,et al.  Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. , 2003, European journal of pharmacology.

[103]  Bryan L Roth,et al.  G-protein-coupled receptors at a glance , 2003, Journal of Cell Science.

[104]  Vadim Cherezov,et al.  Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.

[105]  A. Björklund,et al.  Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model , 2009, Experimental Neurology.

[106]  B. Roth,et al.  Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors , 2009, Front. Mol. Neurosci..

[107]  Dianne M Perez.  From Plants to Man: The GPCR “Tree of Life” , 2005, Molecular Pharmacology.

[108]  C. Rommel,et al.  Strategies for chemokine antagonists as therapeutics. , 2003, Seminars in immunology.

[109]  D. Siderovski,et al.  G-protein signaling: back to the future , 2005, Cellular and Molecular Life Sciences.

[110]  Martin Fussenegger,et al.  A designer network coordinating bovine artificial insemination by ovulation-triggered release of implanted sperms. , 2011, Journal of Controlled Release.

[111]  C. Strader,et al.  Allele-specific activation of genetically engineered receptors. , 1991, The Journal of biological chemistry.

[112]  D. Vigo,et al.  Semen controlled-release capsules allow a single artificial insemination in sows. , 2009, Theriogenology.

[113]  S. Atsumi,et al.  Regulatory circuit design and evolution using phage λ , 2004 .

[114]  Micaela Morelli,et al.  Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease , 2007, Synapse.

[115]  J. Collins,et al.  Construction of a genetic toggle switch in Escherichia coli , 2000, Nature.

[116]  M. Elowitz,et al.  A synthetic oscillatory network of transcriptional regulators , 2000, Nature.

[117]  S. Grundy.  Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy , 2006, Nature Reviews Drug Discovery.

[118]  Masahito Watanabe,et al.  GABA and GABA receptors in the central nervous system and other organs. , 2002, International review of cytology.

[119]  Mario Andrea Marchisio,et al.  In silico implementation of synthetic gene networks. , 2012, Methods in molecular biology.

[120]  Martin Fussenegger,et al.  Smart medication through combination of synthetic biology and cell microencapsulation. , 2012, Metabolic engineering.

[121]  S. Narumiya,et al.  Stress responses: the contribution of prostaglandin E2 and its receptors , 2011, Nature Reviews Endocrinology.

[122]  Martin Fussenegger,et al.  A synthetic mammalian electro-genetic transcription circuit , 2008, Nucleic acids research.

[123]  S. Atsumi,et al.  A synthetic phage λ regulatory circuit , 2006, Proceedings of the National Academy of Sciences.

[124]  Patrick Amar,et al.  BioNetCAD: design, simulation and experimental validation of synthetic biochemical networks , 2010, Bioinform..

[125]  M. Elowitz,et al.  Synthetic Biology: Integrated Gene Circuits , 2011, Science.

[126]  M. Kiebler,et al.  Transfection of Cultured Primary Neurons via Nucleofection , 2009, Current protocols in neuroscience.

[127]  J. Marcu,et al.  Cannabinoid receptors: nomenclature and pharmacological principles , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[128]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[129]  R. Leurs,et al.  A Gq/11-coupled Mutant Histamine H1 Receptor F435A Activated Solely by Synthetic Ligands (RASSL)* , 2005, Journal of Biological Chemistry.

[130]  Jonathan S. Dordick,et al.  Radio-Wave Heating of Iron Oxide Nanoparticles Can Regulate Plasma Glucose in Mice , 2012, Science.

[131]  T. Engber,et al.  Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. , 1994, Neurology.

[132]  Priscilla E. M. Purnick,et al.  The second wave of synthetic biology: from modules to systems , 2009, Nature Reviews Molecular Cell Biology.

[133]  R. Axel,et al.  A novel multigene family may encode odorant receptors: A molecular basis for odor recognition , 1991, Cell.

[134]  J. Ashton.  Cannabinoids for the treatment of inflammation. , 2007, Current opinion in investigational drugs.

[135]  Robert Fredriksson,et al.  The GRAFS classification system of G-protein coupled receptors in comparative perspective. , 2005, General and comparative endocrinology.

[136]  M. Fussenegger,et al.  Design of a novel mammalian screening system for the detection of bioavailable, non-cytotoxic streptogramin antibiotics. , 2001, The Journal of antibiotics.

[137]  M. Spehr,et al.  Olfactory receptors: G protein‐coupled receptors and beyond , 2009, Journal of neurochemistry.

[138]  J. Nelson.  Endothelin receptor antagonists , 2005, World Journal of Urology.

[139]  G. Rayasam,et al.  Fatty acid receptors as new therapeutic targets for diabetes , 2007, Expert opinion on therapeutic targets.

[140]  Linh Tran,et al.  Resistance to diet-induced obesity in mice with synthetic glyoxylate shunt. , 2009, Cell metabolism.

[141]  Gil Alterovitz,et al.  The challenges of informatics in synthetic biology: from biomolecular networks to artificial organisms , 2010, Briefings Bioinform..

[142]  M. Caulfield.  Muscarinic receptors--characterization, coupling and function. , 1993, Pharmacology & therapeutics.

[143]  J. Howl,et al.  Bradykinin receptors as a therapeutic target , 2003, Expert opinion on therapeutic targets.

[144]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[145]  R. A. Hall,et al.  Fine-tuning of GPCR activity by receptor-interacting proteins , 2009, Nature Reviews Molecular Cell Biology.

[146]  Paul S. Freemont,et al.  Computational design approaches and tools for synthetic biology. , 2011, Integrative biology : quantitative biosciences from nano to macro.